Chronic Kidney Disease and Albuminuria
The medical center is at the forefront of research in chronic kidney disease and albuminuria, focusing on innovative therapeutic combinations to improve patient outcomes. The ongoing studies aim to assess the efficacy and safety of novel drug combinations, such as balcinrenone with dapagliflozin, in reducing albuminuria levels more effectively than existing treatments.
- Innovative drug combinations
- Reduction of albuminuria
- Improved patient outcomes
Through these studies, the center contributes significantly to the understanding and management of kidney-related conditions, offering hope for enhanced therapeutic strategies.
Non-Muscle Invasive Bladder Cancer
Specializing in non-muscle invasive bladder cancer, the medical center is conducting advanced research to explore the potential of sasanlimab in combination with Bacillus Calmette-Guerin (BCG) therapy. The focus is on improving event-free survival rates and evaluating the complete response rate in patients who are unresponsive to traditional BCG treatments.
- Combination therapies
- Event-free survival improvement
- Response rate evaluation
This research is pivotal in developing more effective treatment protocols for bladder cancer, particularly for patients with high-risk profiles who have limited options.
